Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Ischemic Heart Disease

Free Subscription Articles published in Lancet Retrieve available abstracts of 113 articles: HTML format

Single Articles

February 2026
1. VALGIMIGLI M, Gragnano F, Giacoppo D
   Clopidogrel versus aspirin for coronary artery disease - Authors' reply.
   Lancet. 2026;407:853-854.
   PubMed    
   
   
   
2. IBRAHIM A, Shalabi L, Ando G
   Clopidogrel versus aspirin for coronary artery disease.
   Lancet. 2026;407:853.
   PubMed    
   
   
   
3. DELLO RUSSO C, Venetucci L, Ramlogan R, Gagliardi D, et al
   Clopidogrel versus aspirin for coronary artery disease.
   Lancet. 2026;407:852-853.
   PubMed    
   
   
   
4. COLLI A, Casazza G, Gluud C
   Clopidogrel versus aspirin for coronary artery disease.
   Lancet. 2026;407:851-852.
   PubMed    
   
   
   
5. XIONG Y, Alemseged F, Cao Z, Schwamm LH, et al
   Tenecteplase versus standard medical treatment for basilar artery occlusion within 24 h (TRACE-5): a multicentre, prospective, randomised, open-label, blinded-endpoint, superiority, phase 3 trial.
   Lancet. 2026 Feb 5:S0140-6736(25)02633-9. doi: 10.1016/S0140-6736(25)02633.
   PubMed     Abstract available
   
   
   
6. TSIVGOULIS G, Palaiodimou L, Turc G
   Intravenous tenecteplase for acute ischaemic stroke within 24 h due to basilar artery occlusion.
   Lancet. 2026 Feb 5:S0140-6736(26)00139-X. doi: 10.1016/S0140-6736(26)00139.
   PubMed    
   
   
   January 2026
7. WENZL FA, Ow KW, Velders MA, Tyrer F, et al
   Prediction of mortality, bleeding, and ischaemic events in patients with cancer and acute coronary syndrome: a model development and validation study.
   Lancet. 2026;407:515-528.
   PubMed     Abstract available
   
   
   
8. LIU JE, Feldman DN
   Cancer and acute coronary syndrome: from risk assessment to personalised clinical decision making.
   Lancet. 2026;407:474-475.
   PubMed    
   
   
   
9. KELSHIKER MA, Bachtiger P, Petri CF, Nakhare S, et al
   Triple cardiovascular disease detection with an artificial intelligence-enabled stethoscope (TRICORDER) in the UK: a cluster-randomised controlled implementation trial.
   Lancet. 2026 Jan 28:S0140-6736(25)02156-7. doi: 10.1016/S0140-6736(25)02156.
   PubMed     Abstract available
   
   
   
10. NAUCK MA, Tuttle KR, Tschop MH, Bluher M, et al
    Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits.
    Lancet. 2026 Jan 14:S0140-6736(25)02105-1. doi: 10.1016/S0140-6736(25)02105.
    PubMed     Abstract available
    
    
    
11. ABIZAID A, Mehran R, Oliva A, Chamie D, et al
    Abluminus DES+ sirolimus-eluting stent versus everolimus-eluting stent in patients with diabetes and coronary artery disease (ABILITY Diabetes Global): results from a multicentre, randomised controlled trial.
    Lancet. 2026 Jan 8:S0140-6736(25)02157-9. doi: 10.1016/S0140-6736(25)02157.
    PubMed     Abstract available
    
    
    December 2025
12. KEDHI E, Hermanides RS, Dambrink JE, Singh SK, et al
    TransCatheter aortic valve implantation and fractional flow reserve-guided percutaneous coronary intervention versus conventional surgical aortic valve replacement and coronary bypass grafting for treatment of patients with aortic valve stenosis and c
    Lancet. 2025;404:2593-2602.
    PubMed     Abstract available
    
    
    
13. TARANTINI G, Cardaioli F
    TAVI and PCI: redefining treatment for aortic stenosis and complex coronary artery disease.
    Lancet. 2025;404:2492-2493.
    PubMed    
    
    
    
14. TAVILDARI A, Dallenbach L, Sierro C, Jovic D, et al
    45-year follow-up after Gruntzig's coronary angioplasty.
    Lancet. 2025;406:2750.
    PubMed    
    
    
    November 2025
15. VAN DER BIJL P, Gulati M, Saraste A, Marwick T, et al
    Contemporary, non-invasive imaging diagnosis of chronic coronary artery disease.
    Lancet. 2025;406:2577-2587.
    PubMed     Abstract available
    
    
    
16. LEE JM
    Complete revascularisation in patients with acute myocardial infarction.
    Lancet. 2025 Nov 9:S0140-6736(25)02243-3. doi: 10.1016/S0140-6736(25)02243.
    PubMed    
    
    
    
17. MEHTA SR, Tiong DTW, Bohm F, Ramasundarahettige C, et al
    Complete versus culprit lesion-only revascularisation for acute myocardial infarction (Complete Revascularisation Trialists' Collaboration): an individual patient data meta-analysis of randomised trials.
    Lancet. 2025 Nov 9:S0140-6736(25)02170-1. doi: 10.1016/S0140-6736(25)02170.
    PubMed     Abstract available
    
    
    
18. SEFEROVIC PM, Polovina MM
    New perspectives on semaglutide in cardiovascular disease.
    Lancet. 2025;406:2198-2200.
    PubMed    
    
    
    
19. CAPODANNO D
    Three-month dual antiplatelet therapy after percutaneous coronary intervention: time for a new standard.
    Lancet. 2025;406:2196-2198.
    PubMed    
    
    
    
20. KANG J, Park KW, Han JK, Hwang D, et al
    Dual antiplatelet therapy after percutaneous coronary intervention according to bleeding risk (HOST-BR): an open-label, multicentre, randomised clinical trial.
    Lancet. 2025;406:2244-2256.
    PubMed     Abstract available
    
    
    October 2025
21. GAO C, Onuma Y, Serruys PW, Tao L, et al
    Drug-coated balloon angioplasty and stenting for coronary artery lesions - Authors' reply.
    Lancet. 2025;406:1951-1952.
    PubMed    
    
    
    
22. RISSANEN TT, Eccleshall S, Jeger R, Latib A, et al
    Drug-coated balloon angioplasty and stenting for coronary artery lesions.
    Lancet. 2025;406:1950-1951.
    PubMed    
    
    
    
23. GURGOGLIONE FL, Cortese B
    Drug-coated balloon angioplasty and stenting for coronary artery lesions.
    Lancet. 2025;406:1950.
    PubMed    
    
    
    
24. SPAULDING C, Eccleshall S, Krackhardt F, Urban P, et al
    Drug-coated balloon angioplasty and stenting for coronary artery lesions.
    Lancet. 2025;406:1949-1950.
    PubMed    
    
    
    
25. LIM PO
    Drug-coated balloon angioplasty and stenting for coronary artery lesions.
    Lancet. 2025;406:1949.
    PubMed    
    
    
    
26. ZHOU T
    Drug-coated balloon angioplasty and stenting for coronary artery lesions.
    Lancet. 2025;406:1948-1949.
    PubMed    
    
    
    
27. HON JJ, Hon JKF
    Plant-based diets for coronary artery disease prevention.
    Lancet. 2025;406:1946-1947.
    PubMed    
    
    
    
28. DEANFIELD J, Lincoff AM, Kahn SE, Emerson SS, et al
    Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial.
    Lancet. 2025 Oct 22:S0140-6736(25)01375-3. doi: 10.1016/S0140-6736(25)01375.
    PubMed     Abstract available
    
    
    August 2025
29. ROSSELLO X, Prescott EIB, Kristensen AMD, Latini R, et al
    beta blockers after myocardial infarction with mildly reduced ejection fraction: an individual patient data meta-analysis of randomised controlled trials.
    Lancet. 2025 Aug 29:S0140-6736(25)01592-2. doi: 10.1016/S0140-6736(25)01592.
    PubMed     Abstract available
    
    
    
30. KIM MC, Ahn JH, Hyun DY, Lim Y, et al
    Immediate versus staged complete revascularisation during index admission in patients with ST-segment elevation myocardial infarction and multivessel disease (OPTION-STEMI): a multicentre, non-inferiority, open-label, randomised trial.
    Lancet. 2025 Aug 28:S0140-6736(25)01529-6. doi: 10.1016/S0140-6736(25)01529.
    PubMed     Abstract available
    
    
    
31. BYRNE RA, Coughlan JJ
    Immediate or staged complete revascularisation in patients with ST segment elevation myocardial infarction.
    Lancet. 2025 Aug 28:S0140-6736(25)01680-0. doi: 10.1016/S0140-6736(25)01680.
    PubMed    
    
    
    
32. UDELL JA, Bahit MC, Campbell P, Butler J, et al
    Prevention of heart failure after acute myocardial infarction.
    Lancet. 2025 Aug 28:S0140-6736(25)01394-7. doi: 10.1016/S0140-6736(25)01394.
    PubMed     Abstract available
    
    
    
33. VERMA S, Leiter LA, Teoh H, Mancini GBJ, et al
    Effect of evolocumab on saphenous vein graft patency after coronary artery bypass surgery (NEWTON-CABG CardioLink-5): an international, randomised, double-blind, placebo-controlled trial.
    Lancet. 2025 Aug 28:S0140-6736(25)01633-2. doi: 10.1016/S0140-6736(25)01633.
    PubMed     Abstract available
    
    
    
34. GAUDINO M, Sandner S
    Evolocumab for prevention of coronary artery bypass failure: timing is everything.
    Lancet. 2025 Aug 28:S0140-6736(25)01718-0. doi: 10.1016/S0140-6736(25)01718.
    PubMed    
    
    
    
35. GUO X, Sun G, Xu Y, Zhou S, et al
    Benefit-harm trade-offs of intensive blood pressure control versus standard blood pressure control on cardiovascular and renal outcomes: an individual participant data analysis of randomised controlled trials.
    Lancet. 2025 Aug 28:S0140-6736(25)01391-1. doi: 10.1016/S0140-6736(25)01391.
    PubMed     Abstract available
    
    
    
36. VALGIMIGLI M, Choi KH, Giacoppo D, Gragnano F, et al
    Clopidogrel versus aspirin for secondary prevention of coronary artery disease: a systematic review and individual patient data meta-analysis.
    Lancet. 2025 Aug 28:S0140-6736(25)01562-4. doi: 10.1016/S0140-6736(25)01562.
    PubMed     Abstract available
    
    
    
37. OSTROMINSKI JW, Cheng AYY, Nelson AJ, Neuen BL, et al
    Cardiovascular, kidney, and metabolic health: an actionable vision for heart failure prevention.
    Lancet. 2025 Aug 28:S0140-6736(25)01384-4. doi: 10.1016/S0140-6736(25)01384.
    PubMed     Abstract available
    
    
    
38. LAM CSP, Cader FA, Chew NWS, Chow CK, et al
    Tackling cardiovascular disease in the Asia-Pacific region: a new Lancet Commission.
    Lancet. 2025 Aug 25:S0140-6736(25)01494-1. doi: 10.1016/S0140-6736(25)01494.
    PubMed    
    
    
    
39. ROSSIGNOL P, Zannad F, Massy Z, Azizi M, et al
    Spironolactone in patients on chronic haemodialysis at high risk of adverse cardiovascular outcomes (ALCHEMIST): a multicentre, double-blind, randomised, placebo-controlled trial and updated meta-analysis.
    Lancet. 2025;406:705-718.
    PubMed     Abstract available
    
    
    July 2025
40. VRINTS C, Andreotti F
    QFR vs FFR for intermediate coronary stenosis.
    Lancet. 2025;406:335.
    PubMed    
    
    
    
41. ANDERSEN BK, Escaned J, Christiansen EH, Holm NR, et al
    QFR vs FFR for intermediate coronary stenosis - Authors' reply.
    Lancet. 2025;406:335-336.
    PubMed    
    
    
    
42. KOMAMURA K, Miyake H, Kobayashi K, Ishiki R, et al
    QFR vs FFR for intermediate coronary stenosis.
    Lancet. 2025;406:334.
    PubMed    
    
    
    
43. ONUMA Y, Tsai TY, Sharif F, Wykrzykowska J, et al
    QFR vs FFR for intermediate coronary stenosis.
    Lancet. 2025;406:334.
    PubMed    
    
    
    
44. ZHU Q, Cheng Y, Wang S
    QFR vs FFR for intermediate coronary stenosis.
    Lancet. 2025;406:333-334.
    PubMed    
    
    
    
45. RODRIGUEZ-GRANILLO GA, Garcia-Garcia HM, Thierer J
    QFR vs FFR for intermediate coronary stenosis.
    Lancet. 2025;406:333.
    PubMed    
    
    
    June 2025
46. CONRAD N, Rahimi K, McMurray JJV, Casadei B, et al
    The changing spectrum of cardiovascular diseases.
    Lancet. 2025 Jun 9:S0140-6736(25)00990-0. doi: 10.1016/S0140-6736(25)00990.
    PubMed    
    
    
    
47. THE LANCET
    From innovation to impact in cardiovascular disease.
    Lancet. 2025;405:2023.
    PubMed    
    
    
    May 2025
48. LEE SJ, Kim BK
    Obicetrapib-ezetimibe combination therapy for patients with atherosclerotic cardiovascular disease.
    Lancet. 2025 May 5:S0140-6736(25)00827-X. doi: 10.1016/S0140-6736(25)00827.
    PubMed    
    
    
    April 2025
49. HUANG C
    Ticagrelor monotherapy for acute coronary syndromes.
    Lancet. 2025;405:1463.
    PubMed    
    
    
    
50. VALGIMIGLI M, Hong SJ, Gragnano F, Hong MK, et al
    Ticagrelor monotherapy for acute coronary syndromes - Authors' reply.
    Lancet. 2025;405:1463-1464.
    PubMed    
    
    
    
51. APOSTOLOS A, Tsigkas G
    Ticagrelor monotherapy for acute coronary syndromes.
    Lancet. 2025;405:1462-1463.
    PubMed    
    
    
    
52. GUO C, Shan D, Liu Z, He F, et al
    Ticagrelor monotherapy for acute coronary syndromes.
    Lancet. 2025;405:1461-1462.
    PubMed    
    
    
    
53. ONIDA S, Davies AH
    Cardiovascular risk assessment in venous disease?
    Lancet. 2025;405:1141-1142.
    PubMed    
    
    
    March 2025
54. CHOI KH, Park YH, Lee JY, Jeong JO, et al
    Efficacy and safety of clopidogrel versus aspirin monotherapy in patients at high risk of subsequent cardiovascular event after percutaneous coronary intervention (SMART-CHOICE 3): a randomised, open-label, multicentre trial.
    Lancet. 2025 Mar 28:S0140-6736(25)00449-0. doi: 10.1016/S0140-6736(25)00449.
    PubMed     Abstract available
    
    
    
55. FEARON WF, Zimmermann FM, Ding VY, Takahashi K, et al
    Outcomes after fractional flow reserve-guided percutaneous coronary intervention versus coronary artery bypass grafting (FAME 3): 5-year follow-up of a multicentre, open-label, randomised trial.
    Lancet. 2025 Mar 28:S0140-6736(25)00505-7. doi: 10.1016/S0140-6736(25)00505.
    PubMed     Abstract available
    
    
    
56. HU X, Zhang J, Yang S, Jiang J, et al
    Angiography-derived fractional flow reserve versus intravascular ultrasound to guide percutaneous coronary intervention in patients with coronary artery disease (FLAVOUR II): a multicentre, randomised, non-inferiority trial.
    Lancet. 2025 Mar 28:S0140-6736(25)00504-5. doi: 10.1016/S0140-6736(25)00504.
    PubMed     Abstract available
    
    
    
57. KIRTANE AJ, Genereux P, Lewis B, Shlofmitz RA, et al
    Orbital atherectomy versus balloon angioplasty before drug-eluting stent implantation in severely calcified lesions eligible for both treatment strategies (ECLIPSE): a multicentre, open-label, randomised trial.
    Lancet. 2025 Mar 28:S0140-6736(25)00450-7. doi: 10.1016/S0140-6736(25)00450.
    PubMed     Abstract available
    
    
    
58. TAM DY, Lee G, Chikwe J
    Fractional flow reserve-guided percutaneous coronary intervention versus coronary artery bypass grafting: please mind the gap.
    Lancet. 2025 Mar 28:S0140-6736(25)00583-5. doi: 10.1016/S0140-6736(25)00583.
    PubMed    
    
    
    
59. COUGHLAN JJ, Byrne RA
    Orbital atherectomy for severely calcified coronary artery lesions.
    Lancet. 2025 Mar 28:S0140-6736(25)00572-0. doi: 10.1016/S0140-6736(25)00572.
    PubMed    
    
    
    
60. ROSSELLO X, Kristensen AMD
    Clopidogrel use in chronic coronary syndrome: a fragile lifelong choice.
    Lancet. 2025 Mar 28:S0140-6736(25)00562-8. doi: 10.1016/S0140-6736(25)00562.
    PubMed    
    
    
    
61. ZAMAN S, Wasfy JH, Kapil V, Ziaeian B, et al
    The Lancet Commission on rethinking coronary artery disease: moving from ischaemia to atheroma.
    Lancet. 2025 Mar 25:S0140-6736(25)00055-8. doi: 10.1016/S0140-6736(25)00055.
    PubMed    
    
    
    
62. THE LANCET
    Rethinking coronary artery disease: a call to action.
    Lancet. 2025 Mar 25:S0140-6736(25)00497-0. doi: 10.1016/S0140-6736(25)00497.
    PubMed    
    
    
    
63. CHANDRASHEKHAR Y, Mensah G, Narula J
    From coronary artery disease to atherosclerotic coronary artery disease: what is in a name?
    Lancet. 2025 Mar 25:S0140-6736(25)00563-X. doi: 10.1016/S0140-6736(25)00563.
    PubMed    
    
    
    
64. WILSON C
    Nancy Brown: using advocacy to advance cardiovascular health.
    Lancet. 2025;405:688.
    PubMed    
    
    
    February 2025
65. XU C
    Inflammatory cardiovascular events and coronary artery disease.
    Lancet. 2025;405:545.
    PubMed    
    
    
    
66. CHAN K, Neubauer S, Channon KM, Deanfield J, et al
    Inflammatory cardiovascular events and coronary artery disease - Authors' reply.
    Lancet. 2025;405:545-546.
    PubMed    
    
    
    
67. ZHAO K, Chen L, Sun Z
    Inflammatory cardiovascular events and coronary artery disease.
    Lancet. 2025;405:544.
    PubMed    
    
    
    
68. NURMOHAMED NS, Beverloo CYY, Kraaijenhof JM, Stroes ESG, et al
    Inflammatory cardiovascular events and coronary artery disease.
    Lancet. 2025;405:544-545.
    PubMed    
    
    
    January 2025
69. WILLIAMS MC, Wereski R, Tuck C, Adamson PD, et al
    Coronary CT angiography-guided management of patients with stable chest pain: 10-year outcomes from the SCOT-HEART randomised controlled trial in Scotland.
    Lancet. 2025;405:329-337.
    PubMed     Abstract available
    
    
    November 2024
70. LUSEBRINK E, Binzenhofer L, Adamo M, Lorusso R, et al
    Cardiogenic shock.
    Lancet. 2024;404:2006-2020.
    PubMed     Abstract available
    
    
    October 2024
71. ANDERSEN BK, Sejr-Hansen M, Maillard L, Campo G, et al
    Quantitative flow ratio versus fractional flow reserve for coronary revascularisation guidance (FAVOR III Europe): a multicentre, randomised, non-inferiority trial.
    Lancet. 2024 Oct 29:S0140-6736(24)02175-5. doi: 10.1016/S0140-6736(24)02175.
    PubMed     Abstract available
    
    
    
72. BECKER LM, Swaans MJ
    Present and future of functional measurements in coronary revascularisation.
    Lancet. 2024 Oct 29:S0140-6736(24)02367-5. doi: 10.1016/S0140-6736(24)02367.
    PubMed    
    
    
    
73. ERLINGE D, Andersson J, Frobert O, Tornerud M, et al
    Bioadaptor implant versus contemporary drug-eluting stent in percutaneous coronary interventions in Sweden (INFINITY-SWEDEHEART): a single-blind, non-inferiority, registry-based, randomised controlled trial.
    Lancet. 2024 Oct 25:S0140-6736(24)02227-X. doi: 10.1016/S0140-6736(24)02227.
    PubMed     Abstract available
    
    
    
74. CAPODANNO D
    Coronary stenting with bioadaptors.
    Lancet. 2024 Oct 25:S0140-6736(24)02359-6. doi: 10.1016/S0140-6736(24)02359.
    PubMed    
    
    
    September 2024
75. THIELE H, Moller JE, Henriques JPS, Bogerd M, et al
    Temporary mechanical circulatory support in infarct-related cardiogenic shock: an individual patient data meta-analysis of randomised trials with 6-month follow-up.
    Lancet. 2024;404:1019-1028.
    PubMed     Abstract available
    
    
    
76. NORDESTGAARD BG, Langsted A
    Lipoprotein(a) and cardiovascular disease.
    Lancet. 2024 Sep 12:S0140-6736(24)01308-4. doi: 10.1016/S0140-6736(24)01308.
    PubMed     Abstract available
    
    
    August 2024
77. KRUMHOLZ HM, Geraldes F, Wilson C, Horton R, et al
    The Lancet-JACC collaboration: advancing cardiovascular health.
    Lancet. 2024;404:833-834.
    PubMed    
    
    
    
78. JENTZER JC, Hibbert B
    Optimal patient and mechanical circulatory support device selection in acute myocardial infarction cardiogenic shock.
    Lancet. 2024 Aug 30:S0140-6736(24)01588-5. doi: 10.1016/S0140-6736(24)01588.
    PubMed    
    
    
    
79. HONG SJ, Lee SJ, Lee SH, Lee JY, et al
    Optical coherence tomography-guided versus angiography-guided percutaneous coronary intervention for patients with complex lesions (OCCUPI): an investigator-initiated, multicentre, randomised, open-label, superiority trial in South Korea.
    Lancet. 2024 Aug 30:S0140-6736(24)01454-5. doi: 10.1016/S0140-6736(24)01454.
    PubMed     Abstract available
    
    
    
80. MAMAS MA, Mintz GS
    Optical coherence tomography imaging for complex percutaneous coronary intervention.
    Lancet. 2024 Aug 30:S0140-6736(24)01593-9. doi: 10.1016/S0140-6736(24)01593.
    PubMed    
    
    
    
81. GAO C, He X, Ouyang F, Zhang Z, et al
    Drug-coated balloon angioplasty with rescue stenting versus intended stenting for the treatment of patients with de novo coronary artery lesions (REC-CAGEFREE I): an open-label, randomised, non-inferiority trial.
    Lancet. 2024 Aug 30:S0140-6736(24)01594-0. doi: 10.1016/S0140-6736(24)01594.
    PubMed     Abstract available
    
    
    
82. MCENTEGART MB, Kirtane AJ
    How feasible is a cage-free solution for de novo coronary artery disease?
    Lancet. 2024 Aug 30:S0140-6736(24)01696-9. doi: 10.1016/S0140-6736(24)01696.
    PubMed    
    
    
    
83. VALGIMIGLI M, Hong SJ, Gragnano F, Chalkou K, et al
    De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient-level meta-analysis of randomised trials.
    Lancet. 2024 Aug 30:S0140-6736(24)01616-7. doi: 10.1016/S0140-6736(24)01616.
    PubMed     Abstract available
    
    
    
84. STEFANINI GG, Oliva A
    Is this the conclusive evidence for ticagrelor monotherapy in acute coronary syndromes?
    Lancet. 2024 Aug 30:S0140-6736(24)01678-7. doi: 10.1016/S0140-6736(24)01678.
    PubMed    
    
    
    
85. DEANFIELD J, Verma S, Scirica BM, Kahn SE, et al
    Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial.
    Lancet. 2024;404:773-786.
    PubMed     Abstract available
    
    
    June 2024
86. LIU J, Li Y, Ge J, Yan X, et al
    Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial.
    Lancet. 2024 Jun 27:S0140-6736(24)01028-6. doi: 10.1016/S0140-6736(24)01028.
    PubMed     Abstract available
    
    
    
87. GAO Y, Li Z, Liu M, Tian J, et al
    VA-ECMO for infarct-related cardiogenic shock.
    Lancet. 2024;403:2487.
    PubMed    
    
    
    
88. YU Z, Li G
    VA-ECMO for infarct-related cardiogenic shock.
    Lancet. 2024;403:2487.
    PubMed    
    
    
    
89. ZEYMER U, Freund A, Hochadel M, Schneider S, et al
    VA-ECMO for infarct-related cardiogenic shock - Authors' reply.
    Lancet. 2024;403:2487-2488.
    PubMed    
    
    
    
90. LI Y
    VA-ECMO for infarct-related cardiogenic shock.
    Lancet. 2024;403:2486.
    PubMed    
    
    
    
91. DALZELL JR
    VA-ECMO for infarct-related cardiogenic shock.
    Lancet. 2024;403:2486.
    PubMed    
    
    
    
92. WANG G, Guan J, Liu Z
    VA-ECMO for infarct-related cardiogenic shock.
    Lancet. 2024;403:2485.
    PubMed    
    
    
    
93. KELLY P, Lemmens R, Weimar C, Walsh C, et al
    Long-term colchicine for the prevention of vascular recurrent events in non-cardioembolic stroke (CONVINCE): a randomised controlled trial.
    Lancet. 2024 Jun 7:S0140-6736(24)00968-1. doi: 10.1016/S0140-6736(24)00968.
    PubMed     Abstract available
    
    
    May 2024
94. CHAN K, Wahome E, Tsiachristas A, Antonopoulos AS, et al
    Inflammatory risk and cardiovascular events in patients without obstructive coronary artery disease: the ORFAN multicentre, longitudinal cohort study.
    Lancet. 2024 May 29:S0140-6736(24)00596-8. doi: 10.1016/S0140-6736(24)00596.
    PubMed     Abstract available
    
    
    
95. COUTTS SB, Ankolekar S, Appireddy R, Arenillas JF, et al
    Tenecteplase versus standard of care for minor ischaemic stroke with proven occlusion (TEMPO-2): a randomised, open label, phase 3 superiority trial.
    Lancet. 2024 May 16:S0140-6736(24)00921-8. doi: 10.1016/S0140-6736(24)00921.
    PubMed     Abstract available
    
    
    April 2024
96. FOLEY MJ, Rajkumar CA, Ahmed-Jushuf F, Simader FA, et al
    Coronary sinus reducer for the treatment of refractory angina (ORBITA-COSMIC): a randomised, placebo-controlled trial.
    Lancet. 2024;403:1543-1553.
    PubMed     Abstract available
    
    
    
97. MONTI CB, Palmisano A
    Coronary sinus reducer: a new hope for refractory angina?
    Lancet. 2024;403:1514-1515.
    PubMed    
    
    
    
98. LI X, Ge Z, Kan J, Anjum M, et al
    Intravascular ultrasound-guided versus angiography-guided percutaneous coronary intervention in acute coronary syndromes (IVUS-ACS): a two-stage, multicentre, randomised trial.
    Lancet. 2024 Apr 5:S0140-6736(24)00282-4. doi: 10.1016/S0140-6736(24)00282.
    PubMed     Abstract available
    
    
    
99. DEN DEKKER WK
    Is intravascular imaging the future of percutaneous coronary intervention?
    Lancet. 2024 Apr 5:S0140-6736(24)00430-6. doi: 10.1016/S0140-6736(24)00430.
    PubMed    
    
    
    
100. GE Z, Kan J, Gao X, Raza A, et al
     Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial.
     Lancet. 2024 Apr 5:S0140-6736(24)00473-2. doi: 10.1016/S0140-6736(24)00473.
     PubMed     Abstract available
     
     
     
101. STEINER-GAGER GM, Siller-Matula JM
     Abbreviated dual antiplatelet therapy after acute coronary syndrome.
     Lancet. 2024 Apr 5:S0140-6736(24)00586-5. doi: 10.1016/S0140-6736(24)00586.
     PubMed    
     
     
     
102. PARK SJ, Ahn JM, Kang DY, Yun SC, et al
     Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): a multicentre, open-label, randomised controlled trial.
     Lancet. 2024 Apr 4:S0140-6736(24)00413-6. doi: 10.1016/S0140-6736(24)00413.
     PubMed     Abstract available
     
     
     
103. BOROVAC JA
     Percutaneous coronary intervention for non-obstructive vulnerable plaques.
     Lancet. 2024 Apr 4:S0140-6736(24)00488-4. doi: 10.1016/S0140-6736(24)00488.
     PubMed    
     
     
     March 2024
104. RIDKER PM, Bhatt DL, Nissen SE
     Inflammation, infection, and cardiovascular risk - Authors' reply.
     Lancet. 2024;403:1025-1026.
     PubMed    
     
     
     
105. SHARMA S, Sharma R
     Inflammation, infection, and cardiovascular risk.
     Lancet. 2024;403:1024-1025.
     PubMed    
     
     
     
106. GOLDMAN M, Bondue A, Cogan E
     Inflammation, infection, and cardiovascular risk.
     Lancet. 2024;403:1023.
     PubMed    
     
     
     
107. GOLDSTEIN MR, Mascitelli L
     Inflammation, infection, and cardiovascular risk.
     Lancet. 2024;403:1023-1024.
     PubMed    
     
     
     
108. DROZD M, Cubbon R
     Inflammation, infection, and cardiovascular risk.
     Lancet. 2024;403:1022-1023.
     PubMed    
     
     
     
109. PAREEK A, Chandurkar N, Naidu K, Raut V, et al
     Inflammation, infection, and cardiovascular risk.
     Lancet. 2024;403:1022.
     PubMed    
     
     
     
110. STRANDBERG TE, Kovanen PT, Gylling H
     Inflammation, infection, and cardiovascular risk.
     Lancet. 2024;403:1021.
     PubMed    
     
     
     
111. LIN GM, Huang WC, Han CL
     Inflammation, infection, and cardiovascular risk.
     Lancet. 2024;403:1021-1022.
     PubMed    
     
     
     February 2024
112. LEE ZS, Ryan N
     Intravascular imaging in percutaneous coronary intervention.
     Lancet. 2024 Feb 21:S0140-6736(23)02686-7. doi: 10.1016/S0140-6736(23)02686.
     PubMed    
     
     
     
113. STONE GW, Christiansen EH, Ali ZA, Andreasen LN, et al
     Intravascular imaging-guided coronary drug-eluting stent implantation: an updated network meta-analysis.
     Lancet. 2024 Feb 21:S0140-6736(23)02454-6. doi: 10.1016/S0140-6736(23)02454.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Ischemic Heart Disease is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum